Stemmatters originated as a spin-off from University of Minho (3B’s Research Group).

Since its creation, Stemmatters strives to create meaningful value from applied biomedical research. Our ambition is to pursue patient benefit by developing novel medical technology that provides more safe and effective regenerative medicine. 
For its operations, Stemmatters integrates research, development and manufacturing capabilities. Stemmatters exploits and develops its core intellectual property independently or as result of strategic collaboration with national and international institutions.

As a pre-clinical stage company, Stemmatters is currently developing game changing medical devices for regenerative medicine applications which offset current competitors and aim to revolutionize standard of care.